Für diesen Artikel ist leider kein Bild verfügbar.

Equitable Access to High-Cost Pharmaceuticals

Buch | Softcover

238 Seiten

2018
Academic Press Inc (Verlag)
978-0-12-811945-7 (ISBN)

Artikel merken

Equitable Access to High-Cost Pharmaceuticals seeks to aid the development and implementation of equitable public health policies by pharmaco-economics professionals, health economists, and policymakers. With detailed country-by country analysis of policy and regulation, the Work compares and contrasts national healthcare systems to support researchers and practitioners identify optimal healthcare policy solutions. The Work incorporates chapters on global regulatory changes, health technology assessment guidelines, and competitive effectiveness research recommendations from international bodies such as the OECD or the EU. Novel policies such as horizon scanning, managed-entry agreement and post-launch monitoring are considered in detail. The Work also thoroughly reviews novel pharmaceuticals with particular research interest, including cancer drugs, orphan medicines, Hep C, and personalized medicines.

With over 25 years of experience in pharmaceutical policy and practice research, Prof Zaheer Babar is a global authority and a prolific author in this field. He comes with a long-standing academic career in pharmacy in New Zealand, and the United Kingdom. He is globally known for his work in policy and practice, including quality use of medicines, and issues related to medicines access and pricing. Prof. Babar has published over 300 papers and is considered the leading researcher in the “pharmacy practice research category. He has published in high-impact journals such as PLoS Medicine and the Lancet and has acted as a consultant for the WHO, RPS, UNDP, HAI, MSH, FIP, International Union Against Tuberculosis and Lung Disease, World Bank, European Union, and the Pharmaceutical Management Agency of New Zealand. His edited work includes "Economic Evaluation of Pharmacy Services", "Pharmaceutical Prices in the 21st Century", "Pharmaceutical Policies in Countries with Developing Healthcare Systems", "Global Pharmaceutical Policy", "Access to high-cost medicines", "Pharmacy Practice Research Methods", "Pharmacy Practice Research Case Studies" , "Encyclopaedia of Pharmacy Practice and Clinical Pharmacy", and "Encyclopaedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy". Published by Elsevier and Adis/Springer, his work is used in curriculum design, policy development, and referral all around the globe. Professor Babar is the founding Editor-In-Chief of the Journal of Pharmaceutical Policy and Practice [IF = 4.2], a high-impact publication that provides evidence-based insights and recommendations for policymakers, practitioners, and researchers. He can be contacted at: z.babar@hud.ac.uk

1. Access to High Cost Medicines: An Overview 2. Health Technology Assessment 3. High-Cost Medicines in England 4. Managed Entry Agreements and High Cost Medicines (European Perspective) 5. Setting a Public Health Agenda to Support Access to High-Cost Medicines 6. Human Rights and Intellectual Property for Universal Access to New Essential Medicines 7. Access to High Price Medicines in Portugal 8. Improving Access to High-Cost Medicines in Low Income Countries in Africa: Creating a Functioning Pharmaceutical System in Uganda 9. Equitable Access to Biosimilars: An Overview 10. Access to High-Cost Medicines in Europe 11. Access to High-Cost Medicines in Australia 12. Access to High-Cost Medicines in New Zealand 13. Access to High-Cost Medicines in Wales

Erscheinungsdatum	24.03.2018
Verlagsort	San Diego
Sprache	englisch
Maße	152 x 229 mm
Gewicht	390 g
Themenwelt	Medizin / Pharmazie ► Gesundheitswesen
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Medizin / Pharmazie ► Pharmazie
	Studium ► Querschnittsbereiche ► Prävention / Gesundheitsförderung
	Technik
	Wirtschaft
ISBN-10	0-12-811945-4 / 0128119454
ISBN-13	978-0-12-811945-7 / 9780128119457
Zustand	Neuware